Please assess the completion status of the following clinical trial:

Trial Title: Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent had to be obtained prior to participation in the study.~2. Patients on established lipid lowering medication or, have been recommended lipid lowering therapy by their health care provider but were unable to tolerate treatment.~3. A total cholesterol measurement at screening that was ≥4 mmol/L \[approximately 160 mg/dL\].~4. Participants on lipid-lowering therapies had to be on a stable dose for ≥30 days before screening with no planned medication or dose change.~Exclusion Criteria:~1. Medical or surgical history that might limit the individual's ability to take study treatments for the duration of the study and/or put the participant at significant risk .~2. Current or planned renal dialysis or transplantation.~3. Acute coronary syndrome or stroke less than 4 weeks before the screening visit.~4. Coronary revascularization procedure planned within the next 6 months.~5. Women of child-bearing potential, unless they agree to abstinence or, if sexually active, agree to the use of effective methods of contraception during the study.~6. Women who are pregnant or breast-feeding.~7. Previous, current or planned treatment with a monoclonal antibody targeting PCSK9, or with a drug known to be contra-indicated with inclisiran.~8. Previous exposure to inclisiran or participation in a randomised study of inclisiran.~9. Current or previous participation in a clinical study with an unlicensed drug or device within 30 days or five half-lives of the screening visit, whichever is longer.~10. Participants who planed to move away from the geographical area where the study is being conducted during the study period.~11. A triglyceride measurement at screening that is greater than or equal to 4.52 mmol/L

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control+ BS (Type: ACTIVE_COMPARATOR): Participants continued to receive their background lipid lowering therapy plus behavioural support (BS).
- Inclisiran (Type: EXPERIMENTAL): Participants continue to receive their background lipid lowering therapy, plus inclisiran for injection (delivered in an injection-only model).
- Inclisiran + BS (Type: EXPERIMENTAL): Participants continued to receive their background lipid lowering therapy, plus inclisiran for injection, plus behavioural support.

Based on this trial design, predict the completion outcome and termination type (if applicable).